SlideShare a Scribd company logo
1 of 22
CARCINOMA PROSTATE
Prostate Treatment Options
ADT in Low Risk Disease
• Common practice in community
• No survival benefit found after 15 years
• Placing patients with early prostate cancer on ADT SHOULD NOT be of routine practice (
NCCN 2017 )
ADT in Intermediate Risk Disease
• Addition of short term ADT to radiation therapy improved OS
• EORTC 22991 : 6 months ADT improved biochemical DFS in intermediate risk
group as compared to radiation alone
ADT in High Risk Disease
• Long duration of ADT is preferred
• Evidence from following trials is available
- RTOG 9202 trial
- EORTC 22863 trial
- DART 01/05 trial
- RTOG 8531
OG 9202
• Group 1
4 months ADT
before and
during RT
• Group 2
4 months ADT before
and during RT
followed by
2 years of ADT
• Subgroup :
GS 8-10, OS benefit
EORTC 22863 trial
• Node-negative patients with clinical stage T3 disease or T1–T2 patients with high-
grade disease
• Received adjuvant ADT on the first day of radiotherapy (prescribed dose of 70 Gy) and
continued for 3 years.
• The 10-year overall survival was 58% versus 40% for patients treated with ADT plus EBRT
and EBRT alone, respectively (p = 0.0004).
PSA level at 7 months (SWOG 9346
cohort)• After starting ADT, the PSA level after 7 months of ADT may lead to 3 groups with very
different survival expectancy.
• The median survival is
75 months if the PSA level < 0.2 ng/mL, 44 months
if the PSA < 4 ng/mL,
13 months if the PSA is > 4 ng/mL.
Enzalutamide
• Enzalutamide is an AR signalling inhibitor that directly targets three stages of the AR
signalling pathway.
• The most common side effects of enzalutamide are fatigue, hypertension, and hot
flushes. In <1% of patients on enzalutamide, seizures occurred.
Evidence : AFFIRM trial
Results
The androgen-signaling axis and
its inhibitors. Testicular androgen
synthesis is regulated by the
gonadotropin-releasing
hormone (GnRH)–LH axis,
whereas adrenal androgen
synthesis is regulated by the
corticotrophin-releasing
hormone (CRH)-ACTH axis. GnRH
agonists and corticosteroids
inhibit stimulation of the testes
and adrenals, respectively.
Abiraterone inhibits CYP17, a
critical enzyme in androgen
synthesis. Bicalutamide,
flutamide, and nilutamide
competitively inhibit the binding
of androgens to androgen
receptors; enzalutamide also
blocks the translocation
of the ligand bound AR complex to the nucleus and from binding to DNA. DHEA,
dehydroepiandrosterone; DHEA-S, dehydroepiandrosterone sulphate; DHT,
dihydrotestosterone; AR, androgen receptor; ARE, androgen-response element.
Enzalutamide :
• A novel anti-androgen that blocks AR binding, nuclear
translocation and transcription.
• Enzalutamide is used as a once-daily oral treatment.
• AFFIRM study in 2012 randomized 1,199 patients with metastatic
CRPC in a 2/1 fashion between enzalutamide or placebo. (The
patients had progressed after docetaxel treatment).
• After a median follow-up of 14.4 months, the median survival in
the enzalutamide group was 18.4 months compared to 13.6 months
in the placebo arm (HR: 0.63, p < 0.001). This led to the
recommendation that the study be halted and unblinded.
• The benefit was observed irrespective of age, baseline pain
intensity, and type of progression.
• CYP17 inhibitor.
• It is used once daily combined with prednisone twice daily (10 mg/ day).
• large phase III COU-AA-301 trial used a total of 1,195 patients with metastatic
CRPC were randomised in a 1/1 fashion between abiraterone acetate or placebo,
In patients with progressive disease after docetaxel therapy the median survival
in the abiraterone group was 15.8 months compared to 11.2 months in the placebo
arm (HR: 0.74, p < 0.001).
• The benefit was observed irrespective of age, baseline pain intensity, and type of
progression.
• most common grade 3/4 side effects did not differ significantly but
mineralocorticoid-related side effects were more frequent in the abiraterone
group, mainly grade 1/2 (fluid retention, oedema or hypokalaemia).
• As of today, the choice between third-line hormonal treatment
(using enzalutamide or abiraterone) or second line
chemotherapy (cabazitaxel) remains unclear with no clear
decision-making findings published.
Abiraterone Acetate
• Bone-seeking radiopharmaceuticals (samarium-153-
EDTMP, strontium-89):
Three radiopharmaceuticals are currently FDA-approved for the
palliative treatment of painful bone metastases
1. phosphorus-32 2.strontium-89 3.samarium-153-EDTMP.
Myelosuppression is the predominate toxicity associated with all of the bone
seeking radioisotopes.
Relative contraindications
• Severe urinary irritative/obstructive symptomatology
• Extensive TURP defect
• Substantial median lobe hyperplasia
• Prostate dimensions larger than the grid (>60 mm in
width & >50mm in height)
• Severe pubic arch interference
• Gross seminal vesicle involvement
• Prior pelvic radiotherapy
• Inflammatory bowel disease
• Pathologic involvement of pelvic lymph nodes
Management of ca prostate
Management of ca prostate
Management of ca prostate

More Related Content

What's hot

Role and Side effects of Ovarian Function Suppression in Breast Cancer
Role  and Side effects of Ovarian Function Suppression in Breast CancerRole  and Side effects of Ovarian Function Suppression in Breast Cancer
Role and Side effects of Ovarian Function Suppression in Breast Cancer
Ajeet Gandhi
 
Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... Prost...
Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... 	 Prost...Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... 	 Prost...
Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... Prost...
MedicineAndHealthCancer
 

What's hot (20)

Role and Side effects of Ovarian Function Suppression in Breast Cancer
Role  and Side effects of Ovarian Function Suppression in Breast CancerRole  and Side effects of Ovarian Function Suppression in Breast Cancer
Role and Side effects of Ovarian Function Suppression in Breast Cancer
 
Total neoadjuvant therapy for rectal cancer 2016
Total neoadjuvant therapy for rectal cancer 2016Total neoadjuvant therapy for rectal cancer 2016
Total neoadjuvant therapy for rectal cancer 2016
 
Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... Prost...
Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... 	 Prost...Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... 	 Prost...
Prostate Cancer: Causes, Diagnosis, and Treatment Options Bruce B ... Prost...
 
Clinically localized prostate cancer Management
Clinically localized prostate cancer ManagementClinically localized prostate cancer Management
Clinically localized prostate cancer Management
 
Radiation therapy in prostate cancer
Radiation therapy in prostate cancer Radiation therapy in prostate cancer
Radiation therapy in prostate cancer
 
Management of advanced prostate carcinoma
Management of advanced prostate carcinomaManagement of advanced prostate carcinoma
Management of advanced prostate carcinoma
 
RADIOTHERAPY IN CARCINOMA OVARY
RADIOTHERAPY IN CARCINOMA OVARYRADIOTHERAPY IN CARCINOMA OVARY
RADIOTHERAPY IN CARCINOMA OVARY
 
PROSTATE CANCER POST OP RADIOTHERAPY
PROSTATE CANCER POST OP RADIOTHERAPYPROSTATE CANCER POST OP RADIOTHERAPY
PROSTATE CANCER POST OP RADIOTHERAPY
 
Prostate cancer , radiotherapy
Prostate cancer , radiotherapyProstate cancer , radiotherapy
Prostate cancer , radiotherapy
 
LOCALLY ADVANCED BREAST CANCER
LOCALLY ADVANCED BREAST CANCERLOCALLY ADVANCED BREAST CANCER
LOCALLY ADVANCED BREAST CANCER
 
Carcinoma prostate stampede trial
Carcinoma  prostate stampede trialCarcinoma  prostate stampede trial
Carcinoma prostate stampede trial
 
Oligometastases
OligometastasesOligometastases
Oligometastases
 
Accelerated partial breast irradiation
Accelerated partial breast irradiationAccelerated partial breast irradiation
Accelerated partial breast irradiation
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancer
 
Radiotherapy practices in GYN malignancies
Radiotherapy practices in GYN malignanciesRadiotherapy practices in GYN malignancies
Radiotherapy practices in GYN malignancies
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniques
 
Intraoperative radiotherapy carcinoma breast
Intraoperative radiotherapy carcinoma breastIntraoperative radiotherapy carcinoma breast
Intraoperative radiotherapy carcinoma breast
 
Prostate
ProstateProstate
Prostate
 
Surgery in cancer prevention
Surgery in cancer preventionSurgery in cancer prevention
Surgery in cancer prevention
 
RECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENTRECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENT
 

Similar to Management of ca prostate

Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
spa718
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
spa718
 
Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomide
seayat1103
 
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatmentMCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
European School of Oncology
 
Salvarani carlo nuovi farmaci biologici torino gennaio 2011_14° convegno pat...
Salvarani carlo nuovi farmaci biologici torino gennaio  2011_14° convegno pat...Salvarani carlo nuovi farmaci biologici torino gennaio  2011_14° convegno pat...
Salvarani carlo nuovi farmaci biologici torino gennaio 2011_14° convegno pat...
cmid
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myeloma
spa718
 
Relapse Myeloma
Relapse MyelomaRelapse Myeloma
Relapse Myeloma
spa718
 

Similar to Management of ca prostate (20)

Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
 
Medical management of prostate cancer
Medical management of prostate cancerMedical management of prostate cancer
Medical management of prostate cancer
 
Apalutamide in metastatic castration resistant prostate cancer
Apalutamide in metastatic castration resistant prostate cancerApalutamide in metastatic castration resistant prostate cancer
Apalutamide in metastatic castration resistant prostate cancer
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
 
Metastatic prostate cancer
Metastatic prostate cancerMetastatic prostate cancer
Metastatic prostate cancer
 
Cancer prostate
Cancer prostateCancer prostate
Cancer prostate
 
Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomide
 
Hr+ mbc
Hr+ mbc Hr+ mbc
Hr+ mbc
 
Resistant urticaria tutorial ppt.
Resistant urticaria tutorial ppt.Resistant urticaria tutorial ppt.
Resistant urticaria tutorial ppt.
 
stampede.pptx
stampede.pptxstampede.pptx
stampede.pptx
 
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatmentMCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
MCO 2011 - Slide 3 - A. Horwich - First-line endocrine treatment
 
GOG 240 Bevacizumab in carcinoma cervix
GOG 240 Bevacizumab in carcinoma cervixGOG 240 Bevacizumab in carcinoma cervix
GOG 240 Bevacizumab in carcinoma cervix
 
Multiple myeloma and plasmacytoma
Multiple myeloma and plasmacytomaMultiple myeloma and plasmacytoma
Multiple myeloma and plasmacytoma
 
Pembrolizumab in advanced melanoma
Pembrolizumab in advanced melanomaPembrolizumab in advanced melanoma
Pembrolizumab in advanced melanoma
 
Salvarani carlo nuovi farmaci biologici torino gennaio 2011_14° convegno pat...
Salvarani carlo nuovi farmaci biologici torino gennaio  2011_14° convegno pat...Salvarani carlo nuovi farmaci biologici torino gennaio  2011_14° convegno pat...
Salvarani carlo nuovi farmaci biologici torino gennaio 2011_14° convegno pat...
 
Prostate carcinoma- hormonal therapy 1
Prostate  carcinoma- hormonal therapy 1Prostate  carcinoma- hormonal therapy 1
Prostate carcinoma- hormonal therapy 1
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myeloma
 
Relapse Myeloma
Relapse MyelomaRelapse Myeloma
Relapse Myeloma
 
Locally Advanced Carcinoma Prostate
Locally Advanced Carcinoma ProstateLocally Advanced Carcinoma Prostate
Locally Advanced Carcinoma Prostate
 

More from DrAyush Garg

More from DrAyush Garg (20)

Overview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsOverview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and Genetics
 
OSTEOSARCOMA
OSTEOSARCOMAOSTEOSARCOMA
OSTEOSARCOMA
 
Overview of brain tumors
Overview of brain tumorsOverview of brain tumors
Overview of brain tumors
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Ear carcinoma
Ear carcinomaEar carcinoma
Ear carcinoma
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
 
Role of palliative care in oncology
Role of palliative care in oncologyRole of palliative care in oncology
Role of palliative care in oncology
 
Breast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingBreast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counselling
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancer
 
Role of hpv in head and neck tumors
Role of hpv in head and neck tumorsRole of hpv in head and neck tumors
Role of hpv in head and neck tumors
 
Carcinoma esophagus
Carcinoma esophagusCarcinoma esophagus
Carcinoma esophagus
 
Cancer vaccines final
Cancer vaccines finalCancer vaccines final
Cancer vaccines final
 
EXTRANODAL EXTENSION
EXTRANODAL EXTENSIONEXTRANODAL EXTENSION
EXTRANODAL EXTENSION
 
Prognostic index in brain metastasis
Prognostic index in brain metastasisPrognostic index in brain metastasis
Prognostic index in brain metastasis
 
Supportive care and quality of life
Supportive care and quality of lifeSupportive care and quality of life
Supportive care and quality of life
 
Palliation brain, spinal and bone mets
Palliation brain, spinal and bone metsPalliation brain, spinal and bone mets
Palliation brain, spinal and bone mets
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
Radiotherapy in CA Penis
Radiotherapy in CA PenisRadiotherapy in CA Penis
Radiotherapy in CA Penis
 
Carcinoma nasopharynx anatomy to management
Carcinoma nasopharynx anatomy to managementCarcinoma nasopharynx anatomy to management
Carcinoma nasopharynx anatomy to management
 

Recently uploaded

Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdfUnveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
NoorulainMehmood1
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
JRRolfNeuqelet
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
claviclebrown44
 

Recently uploaded (20)

Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
 
The Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - Subconscious
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptx
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw material
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
Hi Fi * Surat ℂall Girls Surat Dumas Road 8527049040 WhatsApp AnyTime Best Su...
Hi Fi * Surat ℂall Girls Surat Dumas Road 8527049040 WhatsApp AnyTime Best Su...Hi Fi * Surat ℂall Girls Surat Dumas Road 8527049040 WhatsApp AnyTime Best Su...
Hi Fi * Surat ℂall Girls Surat Dumas Road 8527049040 WhatsApp AnyTime Best Su...
 
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdfUnveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
 
Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
 
Stereochemistry & Asymmetric Synthesis.pptx
Stereochemistry & Asymmetric Synthesis.pptxStereochemistry & Asymmetric Synthesis.pptx
Stereochemistry & Asymmetric Synthesis.pptx
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
duus neurology.pdf anatomy. phisiology///
duus neurology.pdf anatomy. phisiology///duus neurology.pdf anatomy. phisiology///
duus neurology.pdf anatomy. phisiology///
 
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptxGross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
 
Benefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdfBenefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdf
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
 

Management of ca prostate

  • 3. ADT in Low Risk Disease • Common practice in community • No survival benefit found after 15 years • Placing patients with early prostate cancer on ADT SHOULD NOT be of routine practice ( NCCN 2017 )
  • 4. ADT in Intermediate Risk Disease • Addition of short term ADT to radiation therapy improved OS • EORTC 22991 : 6 months ADT improved biochemical DFS in intermediate risk group as compared to radiation alone
  • 5. ADT in High Risk Disease • Long duration of ADT is preferred • Evidence from following trials is available - RTOG 9202 trial - EORTC 22863 trial - DART 01/05 trial - RTOG 8531
  • 6. OG 9202 • Group 1 4 months ADT before and during RT • Group 2 4 months ADT before and during RT followed by 2 years of ADT • Subgroup : GS 8-10, OS benefit
  • 7. EORTC 22863 trial • Node-negative patients with clinical stage T3 disease or T1–T2 patients with high- grade disease • Received adjuvant ADT on the first day of radiotherapy (prescribed dose of 70 Gy) and continued for 3 years. • The 10-year overall survival was 58% versus 40% for patients treated with ADT plus EBRT and EBRT alone, respectively (p = 0.0004).
  • 8. PSA level at 7 months (SWOG 9346 cohort)• After starting ADT, the PSA level after 7 months of ADT may lead to 3 groups with very different survival expectancy. • The median survival is 75 months if the PSA level < 0.2 ng/mL, 44 months if the PSA < 4 ng/mL, 13 months if the PSA is > 4 ng/mL.
  • 9. Enzalutamide • Enzalutamide is an AR signalling inhibitor that directly targets three stages of the AR signalling pathway. • The most common side effects of enzalutamide are fatigue, hypertension, and hot flushes. In <1% of patients on enzalutamide, seizures occurred.
  • 12.
  • 13. The androgen-signaling axis and its inhibitors. Testicular androgen synthesis is regulated by the gonadotropin-releasing hormone (GnRH)–LH axis, whereas adrenal androgen synthesis is regulated by the corticotrophin-releasing hormone (CRH)-ACTH axis. GnRH agonists and corticosteroids inhibit stimulation of the testes and adrenals, respectively. Abiraterone inhibits CYP17, a critical enzyme in androgen synthesis. Bicalutamide, flutamide, and nilutamide competitively inhibit the binding of androgens to androgen receptors; enzalutamide also blocks the translocation of the ligand bound AR complex to the nucleus and from binding to DNA. DHEA, dehydroepiandrosterone; DHEA-S, dehydroepiandrosterone sulphate; DHT, dihydrotestosterone; AR, androgen receptor; ARE, androgen-response element.
  • 14. Enzalutamide : • A novel anti-androgen that blocks AR binding, nuclear translocation and transcription. • Enzalutamide is used as a once-daily oral treatment. • AFFIRM study in 2012 randomized 1,199 patients with metastatic CRPC in a 2/1 fashion between enzalutamide or placebo. (The patients had progressed after docetaxel treatment). • After a median follow-up of 14.4 months, the median survival in the enzalutamide group was 18.4 months compared to 13.6 months in the placebo arm (HR: 0.63, p < 0.001). This led to the recommendation that the study be halted and unblinded. • The benefit was observed irrespective of age, baseline pain intensity, and type of progression.
  • 15. • CYP17 inhibitor. • It is used once daily combined with prednisone twice daily (10 mg/ day). • large phase III COU-AA-301 trial used a total of 1,195 patients with metastatic CRPC were randomised in a 1/1 fashion between abiraterone acetate or placebo, In patients with progressive disease after docetaxel therapy the median survival in the abiraterone group was 15.8 months compared to 11.2 months in the placebo arm (HR: 0.74, p < 0.001). • The benefit was observed irrespective of age, baseline pain intensity, and type of progression. • most common grade 3/4 side effects did not differ significantly but mineralocorticoid-related side effects were more frequent in the abiraterone group, mainly grade 1/2 (fluid retention, oedema or hypokalaemia). • As of today, the choice between third-line hormonal treatment (using enzalutamide or abiraterone) or second line chemotherapy (cabazitaxel) remains unclear with no clear decision-making findings published. Abiraterone Acetate
  • 16. • Bone-seeking radiopharmaceuticals (samarium-153- EDTMP, strontium-89): Three radiopharmaceuticals are currently FDA-approved for the palliative treatment of painful bone metastases 1. phosphorus-32 2.strontium-89 3.samarium-153-EDTMP. Myelosuppression is the predominate toxicity associated with all of the bone seeking radioisotopes.
  • 17.
  • 18.
  • 19. Relative contraindications • Severe urinary irritative/obstructive symptomatology • Extensive TURP defect • Substantial median lobe hyperplasia • Prostate dimensions larger than the grid (>60 mm in width & >50mm in height) • Severe pubic arch interference • Gross seminal vesicle involvement • Prior pelvic radiotherapy • Inflammatory bowel disease • Pathologic involvement of pelvic lymph nodes